Effects of endostatin production on oncogenicity and metastatic activity of HPV16-transformed mouse cells: Role of interleukin 1α

International Journal of Oncology

Volumn 35, Issue 1, 2009, Pages 213-222

  Lakatosova Andelova, Monika ^a   Duskova, Martina ^a   Lucansky, Vincent ^a   Paral, Petr ^a   Vonka, Vladimir ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Endostatin; HPV16 transformed cells; IL 1 ; Metastasizing activity; Oncogenicity

Indexed keywords

ENDOSTATIN; INTERLEUKIN 1ALPHA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CELL LYSATE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; METASTASIS; METASTASIS POTENTIAL; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; VIRUS CARCINOGENESIS; VIRUS CELL TRANSFORMATION;

ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; CULTURE MEDIA, CONDITIONED; ENDOSTATINS; ENDOTHELIAL CELLS; FEMALE; GENES, RAS; INTERLEUKIN-1ALPHA; INTERLEUKIN-2; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 67649442511     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000331     Document Type: Article

References (33)

1. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
2. Abdollahi A, Hahnfeldt P, Maercker C, Gröne HJ, Debus J, Ansorge W, Folkman J, Hlatky L and Huber PE: Endostatin's antiangiogenic signaling network. Mol Cell 13: 649-663, 2004.
3. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST and Kwon YG: Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 60: 5410-5413, 2000.
4. Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, Eder JP, Folkman J and Soker S: Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 63: 8345-8350, 2003.
5. Dixelius J, Cross M, Matsumoto T, Sasaki T, Timpl R and Claesson-Welsh M: Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 62: 1944-1947, 2002.
6. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M and Sukhatme VP: Endostatin induces endothelial cell apoptosis. J Biol Chem 274: 11721-11726, 1999.
7. Smahel M, Sobotkova E, Bubenik J, Simova J, Zak R, Ludvikova V, Hajkova R, Kovarik J, Jelinek F, Povysil C, Marinov J and Vonka V: Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. Br J Cancer 84: 374-380, 2001.
8. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM and Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26, 1996.
9. Janouskova O, Sima P and Kunke D: Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV16 transformed mouse cell: decrease of oncogenicity and induction of protection. Int J Oncol 22: 569-577, 2003.
10. Mikyskova R, Bubenik J, Vonka V, Smahel M, Indrova M, Bieblova J, Simova J and Jandlova T: Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy. Int J Oncol 26: 521-527, 2005.
11. Chen QR, Kumar D, Stass SA and Mixson AJ: Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 59: 3308-3312, 1999.
12. Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P and Libutti SK: Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 60: 1503-1506, 2000.
13. Sauter BV, Martinet O, Zhang WJ, Mandeli J and Woo SL: Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA 97: 4802-4807, 2000.
14. Bazan-Peregrino M, Seymour LW and Harris AL: Gene therapy targeting to tumor endothelium. Cancer Gene Ther 14: 117-127, 2007.
15. Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU and Tanabe KK: Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 59: 6251-6256, 1999.
16. Peroulis I, Jonas N and Saleh M: Antiangiogenic activity of endostatin inhibits C6 glioma growth. Int J Cancer 97: 839-845, 2002.
17. Celik I, Sürücü O, Dietz C, Heymach JV, Force J, Höschele I, Becker CM, Folkman J and Kisker O: Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65: 11044-11050, 2005.
18. Prox D, Becker C, Pirie-Shepherd SR, Celik I, Folkman J and Kisker O: Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg 27: 405-411, 2003.
19. Cui R, Takahashi K, Takahashi F, Tanabe KK and Fukuchi Y: Endostatin gene transfer in murine lung carcinoma cells induces vascular endothelial growth factor secretion resulting in up-regulation of in vivo tumorigenecity. Cancer Lett 232: 262-271, 2006.
20. Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, Kwon YG, Kim TW, Webster KA, Nechustan H and Shin SU: Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Mol Cancer Ther 4: 956-967, 2005.
21. Kawashima H, Waranabe N, Hirose M, Sun X, Atarashi K, Kimura T, Shikata K, Matsuda M, Oqava D, Hejasvaara R, Rehn M, Philajaniemi T and Miyasaka M: Collagen XVIII, a basement membrane heparan sulfate proteoglycan, interacts with L-selectin and monocyte chemoattractant protein-1. J Biol Chem 278: 13069-13076, 2003.
22. Apte RN, Dotan S, Elkabets M, White RW, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y and Voronov E: The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25: 387-408, 2006.
23. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA and Apte RN: IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100: 2645-2650, 2003.
24. Lazar-Molnar E, Hegyesi H, Toth S and Falus A: Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12: 547-554, 2000.
25. Nozaki S, Sledge GW and Nakshatri H: Cancer cell-derived interleukin 1 alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. Biochem Biophys Res Commun 275: 60-62, 2000.
26. Tomimatsu S, Ichikura T and Mochizuki H: Significant correlation between expression ofof interleukin 1 alpha and liver metastasis in gastric carcinoma. Semin Cancer Biol 112: 277-290, 2002.
27. Apte RN and Voronov E: Interleukin 1: a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 12: 277-290, 2002.
28. Chirivi RG, Chiodoni C, Musiani P, Garofalo A, Bernasconi S, Colombo MP and Ciavazzi R: IL-alpha-gene transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. Int J Cancer 67: 856-863, 1996.
29. Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, Wakasugi T, Funahashi H, Sato M, Okada Y, Takeyama H and Manabe T: Interleukin-1α enhances angiogenesis and is associated with liver metastatic potential in human gastric cancer cell lines. J Surg Res 148: 197-204, 2008.
30. Matsuo Y, Sawwai H, Ochi N, Yasuda A, Takahashi H, Funahashi H, Takeyama H and Guha S: Interleukin -1α secreted by pancreatic cancer cells promotes angiogenesis and its therapeutic implications. J Surg Res 153: 274-281, 2009.
31. Wilson RF, Morse MSA, Pei P, Renner RJ, Schuller DE, Robertson FM and Mallery SM: Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells. Anticancer Res 23: 1289-1295, 2003.
32. Yokoyama Y, Sedgewick G and Ramakrishnan S: Endostatin binding to ovarian cancer cells inhibits peritoneal attachement and dissemination. Cancer Res 67: 10813-10822, 2007.
33. Folkman J: Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 312: 594-607, 2006.